142 related articles for article (PubMed ID: 10898702)
1. Fluoroquinolone resistance associated with target mutations and active efflux in oropharyngeal colonizing isolates of viridans group streptococci.
Guerin F; Varon E; Hoï AB; Gutmann L; Podglajen I
Antimicrob Agents Chemother; 2000 Aug; 44(8):2197-200. PubMed ID: 10898702
[TBL] [Abstract][Full Text] [Related]
2. In vitro exchange of fluoroquinolone resistance determinants between Streptococcus pneumoniae and viridans streptococci and genomic organization of the parE-parC region in S. mitis.
Janoir C; Podglajen I; Kitzis MD; Poyart C; Gutmann L
J Infect Dis; 1999 Aug; 180(2):555-8. PubMed ID: 10395882
[TBL] [Abstract][Full Text] [Related]
3. Drug efflux and parC mutations are involved in fluoroquinolone resistance in viridans group streptococci.
Ferrándiz MJ; Oteo J; Aracil B; Gómez-Garcés JL; De La Campa AG
Antimicrob Agents Chemother; 1999 Oct; 43(10):2520-3. PubMed ID: 10508036
[TBL] [Abstract][Full Text] [Related]
4. Fluoroquinolone resistance in atypical pneumococci and oral streptococci: evidence of horizontal gene transfer of fluoroquinolone resistance determinants from Streptococcus pneumoniae.
Ip M; Chau SS; Chi F; Tang J; Chan PK
Antimicrob Agents Chemother; 2007 Aug; 51(8):2690-700. PubMed ID: 17548487
[TBL] [Abstract][Full Text] [Related]
5. Antibiotic resistance rates and macrolide resistance phenotypes of viridans group streptococci from the oropharynx of healthy Greek children.
Ioannidou S; Tassios PT; Kotsovili-Tseleni A; Foustoukou M; Legakis NJ; Vatopoulos A
Int J Antimicrob Agents; 2001 Mar; 17(3):195-201. PubMed ID: 11282264
[TBL] [Abstract][Full Text] [Related]
6. Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci.
Kaneko A; Sasaki J; Shimadzu M; Kanayama A; Saika T; Kobayashi I
J Antimicrob Chemother; 2000 Jun; 45(6):771-5. PubMed ID: 10837428
[TBL] [Abstract][Full Text] [Related]
7. Species-level assessment of the molecular basis of fluoroquinolone resistance among viridans group streptococci causing bacteraemia in cancer patients.
Sahasrabhojane P; Galloway-Peña J; Velazquez L; Saldaña M; Horstmann N; Tarrand J; Shelburne SA
Int J Antimicrob Agents; 2014 Jun; 43(6):558-62. PubMed ID: 24721231
[TBL] [Abstract][Full Text] [Related]
8. ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae.
Varon E; Janoir C; Kitzis MD; Gutmann L
Antimicrob Agents Chemother; 1999 Feb; 43(2):302-6. PubMed ID: 9925523
[TBL] [Abstract][Full Text] [Related]
9. In vitro activities of fluoroquinolones against antibiotic-resistant blood culture isolates of viridans group streptococci from across Canada.
de Azavedo JC; Trpeski L; Pong-Porter S; Matsumura S; Low DE
Antimicrob Agents Chemother; 1999 Sep; 43(9):2299-301. PubMed ID: 10471583
[TBL] [Abstract][Full Text] [Related]
10. Target site modifications and efflux phenotype in clinical isolates of Streptococcus pneumoniae from Hong Kong with reduced susceptibility to fluoroquinolones.
Ho PL; Yam WC; Que TL; Tsang DN; Seto WH; Ng TK; Ng WS
J Antimicrob Chemother; 2001 May; 47(5):655-8. PubMed ID: 11328779
[TBL] [Abstract][Full Text] [Related]
11. Interspecies recombination contributes minimally to fluoroquinolone resistance in Streptococcus pneumoniae.
Bast DJ; de Azavedo JC; Tam TY; Kilburn L; Duncan C; Mandell LA; Davidson RJ; Low DE
Antimicrob Agents Chemother; 2001 Sep; 45(9):2631-4. PubMed ID: 11502541
[TBL] [Abstract][Full Text] [Related]
12. Expression of efflux pump gene pmrA in fluoroquinolone-resistant and -susceptible clinical isolates of Streptococcus pneumoniae.
Piddock LJ; Johnson MM; Simjee S; Pumbwe L
Antimicrob Agents Chemother; 2002 Mar; 46(3):808-12. PubMed ID: 11850265
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms and spread of fluoroquinolone resistance in Streptococcus pneumoniae.
Varon E; Gutmann L
Res Microbiol; 2000; 151(6):471-3. PubMed ID: 10961461
[TBL] [Abstract][Full Text] [Related]
14. Fluoroquinolone resistance is a poor surrogate marker for type II topoisomerase mutations in clinical isolates of Streptococcus pneumoniae.
Millichap JJ; Pestova E; Siddiqui F; Noskin GA; Peterson LR
J Clin Microbiol; 2001 Jul; 39(7):2719-21. PubMed ID: 11427605
[TBL] [Abstract][Full Text] [Related]
15. Topoisomerase mutations associated with in vitro selection of resistance to moxifloxacin in Streptococcus pneumoniae.
Houssaye S; Gutmann L; Varon E
Antimicrob Agents Chemother; 2002 Aug; 46(8):2712-5. PubMed ID: 12121964
[TBL] [Abstract][Full Text] [Related]
16. Horizontal transfer of parC and gyrA in fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae.
Ferrándiz MJ; Fenoll A; Liñares J; De La Campa AG
Antimicrob Agents Chemother; 2000 Apr; 44(4):840-7. PubMed ID: 10722479
[TBL] [Abstract][Full Text] [Related]
17. Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae.
Weigel LM; Anderson GJ; Facklam RR; Tenover FC
Antimicrob Agents Chemother; 2001 Dec; 45(12):3517-23. PubMed ID: 11709333
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of susceptibility testing to detect fluoroquinolone resistance mechanisms in Streptococcus pneumoniae.
Richardson DC; Bast D; McGeer A; Low DE
Antimicrob Agents Chemother; 2001 Jun; 45(6):1911-4. PubMed ID: 11353652
[TBL] [Abstract][Full Text] [Related]
19. Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones.
Pestova E; Beyer R; Cianciotto NP; Noskin GA; Peterson LR
Antimicrob Agents Chemother; 1999 Aug; 43(8):2000-4. PubMed ID: 10428926
[TBL] [Abstract][Full Text] [Related]
20. Role of topoisomerase mutations and efflux in fluoroquinolone resistance of Bacteroides fragilis clinical isolates and laboratory mutants.
Ricci V; Peterson ML; Rotschafer JC; Wexler H; Piddock LJ
Antimicrob Agents Chemother; 2004 Apr; 48(4):1344-6. PubMed ID: 15047539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
